Background:

Mifepristone (RU486) is a potent antagonist of progesterone receptor, used as a contraceptive agent [1].

As a contraceptive agent, Mifepristone has been reported to reduce the size of uterine fibroids, and inhibit the growth of meningioma cells in vitro, in experimental animal models and in patients with inoperable meningiomas. As a non-contraceptive action, Mifepristone was been revealed to inhibit the proliferation of normal and malignant endometrial cells, breast cancer cells, prostate cancer cells and gastric adenocarcinoma cell lines. In addition, Mifepristone has been demonstrated to have progesterone-like effects and suppression ovarian cancer cell growth in a dose-dependent fashion with the IC50 values of 6.25μmol/l and 6.91μmol/l for SK-OV-3 and OV2008 cell lines, respectively [1].

参考文献:
[1] Goyeneche AA1, Carón RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007 Jun 1; 13(11):3370-9.